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Abstract
Epstein–Barr virus (EBV) is important in the development of post-transplant lymphoproliferative disease in allogeneic stem cell and solid
organ transplant recipients. We have studied the clinical signiﬁcance of EBV DNAaemia among nontransplant patients in a tertiary refer-
ral hospital. We retrospectively reviewed the medical records for main diagnosis, outcome, immunosuppressive/cytotoxic chemotherapy
and other opportunistic infections of the patients who were found positive in quantitative real-time PCR assay for EBV (EBV-qPCR)
between the years 2000 and 2007. Allogeneic stem cell and solid organ transplant recipients were excluded, and all patients in nonsurgi-
cal adult wards were included. Altogether, 62 patients had at least one plasma sample positive with an EBV-qPCR. Fifteen were immu-
nocompetent, most had primary EBV infection, and the outcome was good. On the other hand, 36 had malignant disease, seven had
HIV infection and seven had immunosuppressive conditions of an other aetiology. All but one of the malignancies were of lymphoid ori-
gin, and most of these patients had a history of multiple cytotoxic treatments. Immunosuppressed patients had higher viral loads. EBV
viraemia is associated with severe immunosuppression and lymphoid malignancies.
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Introduction
Epstein–Barr virus (EBV) is a ubiquitous gammaherpesvirus
infecting over 90% of the world population and it is the caus-
ative agent of infectious mononucleosis. Reactivation of
latent EBV is clinically signiﬁcant in immunocompromised
patients and may lead to life-threatening post-transplant
lymphoproliferative disease (PTLD) [1].
Nucleic acid ampliﬁcation techniques have greatly
improved our ability to detect EBV infections. Quantitative
EBV-PCR is widely used in the diagnostic workup of diverse
patient groups, besides allogeneic stem cell or solid organ
transplant recipients.
Most studies on the signiﬁcance of EBV viral load have
until now concentrated on preselected patients with a
particular diagnosis. Quantiﬁcation of EBV viral load has
been shown to be of high value in the early diagnosis of
PTLD, in pre-emptive treatment and in monitoring of treat-
ment response among allogeneic stem cell transplant recipi-
ents [2,3], solid organ transplant recipients [4], as well as
in patients with nasopharyngeal carcinoma [5] or EBV-posi-
tive Hodgkin’s disease [6]. We have determined the under-
lying or associated diseases and outcomes in adult patients
in a tertiary care hospital who were found to be EBV-posi-
tive in plasma by using a quantitative PCR test. Allogeneic
stem cell and solid organ transplant recipients were
excluded.
Materials and methods
Patients
We analysed retrospectively the clinical and laboratory
records of the patients found to be positive in a quantitative
plasma real-time EBV-PCR assay during the period 2000–
2007. The requests for the PCR examinations came from
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individual clinicians on clinical grounds only (i.e. without
knowledge of this study).
Laboratory data from all non-operative adult wards of the
Helsinki University Hospital were retrieved from the elec-
tronic record of the Department of Virology, Laboratory
Division, Helsinki University Central Hospital. The wards
included infectious diseases, haematology, nephrology,
gastroenterology, cardiology, pulmonology, rheumatology,
neurology and general internal medicine, as well as the emer-
gency room and the medical intensive care unit. Allogeneic
stem cell and solid organ transplant recipients were excluded
from the investigation. The study was approved by the ethi-
cal and personal data security authorities of the hospital.
The underlying main diseases present during viraemia or
diagnosed at the same time (e.g. haematological malignancy,
HIV) were retrieved from patient records and the pathol-
ogy database. Further, the immunosuppressive/cytotoxic
treatments received before or during viraemia were
recorded, as were other opportunistic pathogens detected
[e.g. cytomegalovirus (CMV), Pneumocystis jirovecii, fungi,
polyomavirus], possible treatment against EBV (e.g. ritux-
imab), disease outcome and date of death, when applicable.
When available, results of EBV serology including viral cap-
sid antigen-IgG, IgM and IgG avidity [7] were recorded to
assess whether or not the viraemia was that of primary
infection.
EBER in situ hybridization
In some of the patients, the malignant tissue had been stud-
ied by in situ hybridization for the presence of EBV-encoded
RNA (EBER 1). This was performed on parafﬁn sections
using a ﬂuorescein-labelled peptide nucleic acid EBER-1
probe (Dako, Glostrup, Denmark) and assayed using the
Ventana ES automated slide stainer (Ventana Medical
Systems, Tucson, AZ, USA), with a secondary anti-ﬂuores-
cein antibody (Boehringer Mannheim, Mannheim, Germany)
and Ventana DAB detection kit (Ventana Medical Systems).
EBV PCR
Before May 2002, the DNA was isolated by phenol-chloro-
form extraction and after that date by using the MagNaPure
LC Instrument (Roche Diagnostics, Basel, Switzerland) [8].
The quantitative real-time EBV PCR assay with plasma sam-
ples was performed as previously described [9]. Brieﬂy, the
primers amplifying a conserved sequence of viral DNA poly-
merase (BALF5) gene and a ﬂuorogenic probe for this area
described by Kimura et al. [10] were used at a primer con-
centration of 0.9 lM and a probe concentration of 0.25 lM.
The ampliﬁcation was carried out in an ABI PRISM 7900 HT
Sequence Detector (PE Applied Biosystems, Foster City, CA,
USA) and the standard curve was created with the Sequence
Detection System software by plotting the CT values against
known EBV-DNA concentrations. The assay has a detection
limit of 500 copies/mL.
Statistical analysis
The difference in maximum viral load between groups was
assessed by Mann–Whitney U-test or Aspin–Welch t-test
when applicable. Frequency data were analysed by Fisher’s
exact test. For all statistical analyses, SPSS 15.0 for Windows
(SPSS Inc., Chicago, IL, USA) was used.
Results
EBV DNAemia occurs predominantly in patients with
lymphoid malignancies
In total, we found 62 patients (who had not received alloge-
neic transplant) with a positive result in the quantitative
real-time EBV PCR (Table 1). There were one to 18 samples
per patient. Of these 62 patients, 15 were classiﬁed as immu-
nocompetent. In this group, the EBV infections occurred at
the age of 16–50 years (median 25 years). Eleven of these
patients had serology consistent with a primary infection
(IgM positive and IgG avidity low), two showed an apparent
reactivation (high IgG and IgG avidity, negative IgM) and two
could not be classiﬁed.
The remaining 47 patients were immunocompromised.
Seven patients had HIV/AIDS, 36 had malignant disease (includ-
ing three with HIV) and seven patients had an immunosuppres-
sive treatment or status of another type. The malignancies are
TABLE 1. Main diagnoses of the Epstein–Barr virus-positive
patients
Immunocompetenta 15
HIV 7
Malignant disease 36
Chronic lymphocytic leukaemia 12
T cell lymphoma 7
Myeloma 4
Other lymphomab 7
Mb Hodgkinc 5
Acute myeloid leukaemia 1
Other immunosuppression 7
Ankylosing spondylitis, steroid + antiTNF 1
COP, steroids 1
Crohn’s disease, steroids + aza + antiTNF 1
Coeliac disease, steroids + aza + tacro 1
Autoimmune hepatitis, steroids + aza + mercaptopurine 1
Aplastic anaemia 1
Multiple nonmalignant morbidity 1
aOne sarcoidosis + steroids over 20 years ago, one alcohol liver disease, others
previously healthy.
bTwo HIV patients.
cOne HIV patient.
aza, azathioprine; COP, cryptogenic organizing pneumonia; tacro, tacrolimus
TNF, tumour necrosis factor.
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listed in Tables 1 and 2. Strikingly, all but one were of lymphoid
origin. The most common diagnoses were chronic lymphocytic
leukaemia (CLL), T-cell lymphoma and other lymphomas. Only
one myeloid malignancy was included.
For comparison, during the study period, 240 patients
with a neoplastic haematological diagnosis (and no allogeneic
transplant) were found to be negative in all their EBV PCR
tests. One hundred and eighty-seven of these were lymphoid
neoplasias (35 CLL) and 53 were of myeloid origin compared
to 35 lymphoid and one myeloid neoplasia in the PCR posi-
tive group (OR 9.920, CI, 1328–77, 111, Fisher’s exact test
p ¼ 0.003). The total and annual numbers of plasma EBV
quantitative (q)PCR assays performed on the wards included
in the study are shown in Table 3.
From 11 of the 36 patients with malignancy, EBV serol-
ogy was available. All had high IgG levels (titre in the range
130 to >2300) and IgM was negative in seven. IgG avidity
was high in all these patients, ruling out acute primary
infection.
Mortality in EBV-DNA positive haematological patients
Of the 36 EBV-PCR-positive patients with malignant disease,
29 died during the observation period. The mortality rate at
3 months from the ﬁrst sample was 42% in this group. The
two deaths of HIV patients were caused by lymphoma.
The EBV viral load could not independently predict
mortality in this heterogeneous material (data not shown).
In the 36 patients with malignancy, the EBV viral load in
the last sample before death or at the end of follow-up
was undetectable (<500 copies/mL) in 11 patients, <10 000
copies in 17 and >10 000 copies in eight. The corresponding
overall mortality rates were 73%, 82% and 88%, respectively.
TABLE 2. Clinical characteristics of the patients with malignancy
Age Sex Diagnosis EBER Fludarabine Alemtuzumab
Autologous
transplantation
(time from peak EBV)
Survival
time (day)
Peak EBV PCR
copies/mL
32 M HIV, extranodal lymphoblastic lymphoma ) 360 18 500
29 F HIV, Hodgkin mixed cellularity + Alive (2450) 16 400
26 M HIV, large B-cell lymphoma ) 84 9900
62 F CLL +(+6 months) Alive (2385) 1530
59 M CLL + + 42 29 800
51 F CLL + + +()5 years) 902 10 480
60 F CLL + + +()3 years) 467 3300
75 F CLL + 84 7670
66 F CLL 551 1400
54 F CLL + +()17 months) 3 600
67 F CLL, blast transformation + 327 455 800
64 F CLL, glioma + +()1 month) 564 1753
66 M CLL, histiocytic lymphoma + 46 3060
57 M CLL, Mb Hodgkin + Alive (428) 48 900
70 M CLL 2 2000
42 M Peripheral T-cell lymphoma 37 102 000
69 M Periphral T lymphoma + 234 3300
35 M T/NK lymphoma + + 16 1 900 000
71 M T-cell lymphoma ) 226 98 370
45 M T-cell lymphoma ) 67 30 000
63 F T-prolymphocytic leukaemia + + 56 13 250
49 F T-cell lymphoma (angioimmunoblastic) +(+4 months) Alive (695) 15 500
66 M B-ALL/lymphoblastic lymphoma + 314 23 400
73 M B-cell lymphoma + 858 475 200
86 M diffuse large B-cell lymphoma + 37 333 200
70 M Non-Hodgkin lymphoma + 545 899 000
29 M Mb Hodgkin ) Alive (1979) 1900
27 M Mb Hodgkin + +(+8 months) Alive (640) 550
20 M Mb Hodgkin Alive (1517) 2800
26 M MbHodgkin Alive (1238) 3000
63 F Myeloma +()1 month) 53 3580
77 M Myeloma 114 4900
73 F Myeloma, amyloidosis 2 1040
77 M Myeloma, plasma cell leukemia 32 1200
71 M Hairy cell leukaemia, microcellular carcinoma 23 1287
70 M AML 125 2185
CLL, chronic lymphocytic leukaemia; EBER, EBV-encoded RNA; EBV, Epstein–Barr virus; NK, natural killer.
TABLE 3. Total numbers of plasma Epstein–Barr virus
quantitative PCR tests in the wards included in the study
Year
Number of
tests
Number of
patients tested
Tests in
haematology
2000 300 112 253
2001 628 170 523
2002 990 236 819
2003 1005 308 842
2004 829 293 647
2005 666 275 458
2006 535 273 263
2007 (up to 30 April 2007) 173 113
Total 5126 1780
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Most of the haematological patients with EB viraemia are
heavily immunosuppressed
The majority of the patients with malignant disease and EB
viraemia had a history of repeated cytotoxic treatments.
Nine of 12 patients with CLL had received ﬂudarabine (with
a time interval between last administration of ﬂudarabine and
ﬁrst positive EBV qPCR in the range 0 months to 4 years)
and three alemtuzumab (0, 5 and 11 months before peak vi-
raemia). Two of seven patients with T-cell lymphoma had
received alemtuzumab (0 and 11 months before peak vira-
emia) (Table 2). Five of the patients with a malignant disease
had received an autologous stem cell transplant before the
peak EBV qPCR (1 month to 5 years, median 17 months;
one patient had 3 years to ﬁrst viremic sample and 5 years
to peak EBV-qPCR value (Table 2). Three additional patients
received an autologous transplant later during the observa-
tion period.
Twenty of the 36 patients with a malignancy and EB-
viraemia also had microbiological evidence of another oppor-
tunistic pathogen [12 CMV, four pneumocystis, four fungi,
four Herpes simplex virus, three polyomavirus (BK virus),
three mycobacteria (one Mycobacterium tuberculosis, one
Mycobacterium avium), two varicella-zoster virus, one Listeria
monocytogenes]. The CMV DNAaemia/antigenaemia was
detected at median 0 months before the ﬁrst positive EBV-
qPCR (range 1 month before to 19 months after). Seven of
the CMV viraemias occurred within 1 month of the EB
viremia. The other opportunistic infections were found
within 2 months of ﬁrst positive EBV-qPCR in nine cases.
The CD4+ T-cell count had been studied in 18 HIV-
negative patients with malignancy. The median CD4+ T-cell
count in these patients was 246 (range 19–1935) cells/lL.
The seven HIV patients (three of these with lymphoma)
were deeply immunosuppressed at the time of viraemia, and
ﬁve had other opportunistic infections (three CMV, one
pneumocystis, one histoplasmosis, two mycobacteria, one
Kaposi’s sarcoma, one polyomavirus, one toxoplamosis). The
other opportunistic infections were detected within 1 month
of the ﬁrst positive EBV qPCR in four of these patients.
Among HIV patients, the patient with the highest CMV viral
load and, in addition to histoplasmosis, also had the highest
EBV copy number.
The median CD4+ T-cell count (in the sample closest to
the onset of EB viremia) was 63 (range 9–491) cells/lL.
The EBV load is higher in the immunocompromised
patients
When the peak EBV plasma loads were compared in the
patients classiﬁed as immunocompetent and in those who
were immunosuppressed (pooled HIV, malignancy and
other immunosuppression), only two of 15 (13%) of the
former had over 10 000 copies of EBV DNA/mL, in con-
trast to 19 of 47 (40%) of the immunosuppressed patients
(Fig. 1).
However, the highest viral load in the entire study,
20 million copies/mL, was found in an immunocompetent
50-year-old man with primary EBV infection, who recovered
well. Excluding this outlier, the viral loads were signiﬁcantly
higher in the immunocompromised compared to the immuno-
competent patients (mean ± SD: 115 682 ± 328 056 copies/
mL vs. 4202 ± 3186 copies/mL, p 0.024 Aspin–Welch t-test).
In patients with other documented opportunistic infections,
the mean peak EBV load was 102 597 ± 243 707 copies/mL.
Fludarabine may predispose CLL patients to higher EBV
loads
Among the CLL patients receiving ﬂudarabine, the mean
peak EBV load was 62 374 ± 148 412 copies/mL compared
to 1643 ± 315 copies/mL among those not receiving the
drug (p 0.079 Mann–Whitney U-test).
Rituximab treatment
Overall, 13 patients with a malignancy received rituximab.
According to the patient records, at least one course of the
drug had been aimed at EBV because of clinicians’ suspicion
of EBV-associated lymphoproliferative disease in 11 of these
patients.
FIG. 1. The distribution of peak Epstein–Barr virus (EBV) DNA copy
numbers in plasma of immunocompetent and immunosuppressed
patients. In the box plots, median, interquartile range, extremes and
outliers are shown. The y-axis depicts values of EBV DNA in log10 of
copies/mL. In addition, dot blots of individual values are shown next
to the box plot. When one outlier (patient no. 15 in the immuno-
competent group) is removed, the difference is signiﬁcant (p <0.05,
t-test for unequal variances).
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The absolute viral load decreased signiﬁcantly more
rapidly in the patients treated with rituximab during viraemia
(38343 ± 102521 copies/day in comparison with 866 ±
1502 copies/day in the patients with malignancy not treated
with rituximab, p 0.025 Mann–Whitney U-test). In addition,
however, the peak EBV load was signiﬁcantly higher in the
rituximab-treated patients (mean peak EBV load 323 319 ±
572 249 copies/mL vs.73 901 ± 15 755 copies/mL, p ¼ 0.002
Mann–Whitney U-test). Therefore, the relative rate of
decrease in the two groups was not signiﬁcantly different
(7.6 ± 5.7%/day vs. 9.7 ± 11%/day, respectively). Naturally,
only patients with more than one EBV qPCR measurement
were included in this analysis.
Patients with EBER-positive lymphomas
The patients with EBER-positive lymphomas (n = 8) mostly
had high or increasing EBV viral loads at diagnosis or acceler-
ation of the disease (mean peak viral load 456 381 ±
664 357 copies/mL vs. 31 275 ± 87 294 copies/mL in the
patients with EBER-negative malignancy p ¼ 0.035, Mann–
Whitney U-test).
Patients with other immunosuppressive states
The other immunosuppressive states were mostly autoim-
mune diseases treated with immunosuppression, steroids and
azathioprine (Table 1). One patient had aplastic anaemia and
one had multiple nonmalignant diseases. Interestingly, two of
the seven patients in this group had been previously treated
with tumour necrosis factor a-antagonists (one for ankylosing
spondylitis, the other for Crohn’s disease). The latter patient
had a primary EBV infection with a fulminant and fatal course.
Discussion
The present study describes the clinical spectrum of EB
viraemias in a tertiary care hospital setting, excluding alloge-
neic stem cell or solid organ transplant recipients. Some
primary infections among immunocompetent individuals also
require hospital care, with patients having a higher average
age and more severe clinical presentation than in the general
population [11]. Nevertheless, our series included also some
typical mononucleoses in healthy young adults. Most of our
patients were immunosuppressed and, strikingly, many had
malignancies of lymphoid origin. In addition, most of the lat-
ter patients had a history of multiple cytotoxic treatments.
In general, in our study, immunosuppression was associated
with higher EBV copy numbers. The serological data from 11
of the 36 patients with malignancies indicated that most of
the viraemias in this patient group represented EBV reactiva-
tions.
It is well established that cell-mediated immunity is impor-
tant in the control of EBV reactivation [3,12]. In lymphomas
and lymphoid leukaemias, the disease itself leads to greater
disturbance in lymphocyte development and function than
in myeloid malignancies [13]. In addition, the therapeutic
regimens used in lymphomas and lymphoid leukaemias, espe-
cially T-cell lymphomas and CLL, tend to be more suppres-
sive of cell mediated immunity. This is especially true for
ﬂudarabine and alemtuzumab [13].
Within the group of malignant disease and EB viraemia,
almost all patients succumbed, reﬂecting the high morbidity
among this patient group. The lack of association with sur-
vival in our material partly derives from very advanced cases
where a single low EBV viral load was found shortly before
death. In these cases, the low level EBV viraemia may merely
be a marker of profound immunosuppression. On the other
hand, high viral loads detected at the time of diagnosis or
relapse of the lymphatic malignancy could well be prognosti-
cally signiﬁcant.
In the patients with EBER-positive lymphatic malignancy,
the EBV DNA in plasma may represent fragments of viral
DNA released from dying infected tumour cells rather than
whole virions released from lytically infected cells [14].
Therefore, the viral loads in these patients are not totally
comparable with those in non-EBV-associated malignancy.
The present study does have several limitations. First, it is
retrospective in nature. Second, the requests for EBV PCR
were from a large number of individual clinicians, in the
absence of uniform criteria. We have no data concerning the
patients whom they decided not to test. Furthermore, the
data were collected from a number of subspecialties of medi-
cine, even though haematology and infectious diseases
predominated. The small number of patients from rheuma-
tology and nephrology on one hand, and the large number of
haematological patients on the other hand, reveals a
difference between specialties in the index of suspicion of
EBV-induced illness.
In conclusion, the present study shows that Epstein–Barr
viraemia is associated with severe immunosuppression and
lymphoid malignancies in patients who have not received
allogeneic transplants.
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